ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery
This interview with Dr Monty Pal, Associate Professor from the [...]
Medicine and clinical trial supplies after Brexit
The UK is due to leave the EU on 31 [...]
Metastasectomy followed by targeted therapy does not improve survival
The following video interview with Dr Elizabeth Plimack from the [...]
GRANT score: A new tool to predict survival in kidney cancer patients
A recent study, published in Scientific Reports last month, describes [...]
Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer
A recent phase 1b clinical trial investigated the use of [...]
Liquid biopsies in the era of immuno-oncology
This review, published in the Annals of Oncology, discusses the [...]
ESMO 2019: Neurologic complications of immunotherapy
This interview with Dr Matthias Preusser from the Medical University of [...]
ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis
Results from the ADAPTeR study to evaluate the role of [...]
ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy
Results from a post-hoc analysis of JAVELIN-Renal 101 in patients [...]
